Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Barclays PLC raised its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 292.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,599 shares of the company's stock after purchasing an additional 42,926 shares during the quarter. Barclays PLC owned 0.11% of Zevra Therapeutics worth $399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZVRA. International Assets Investment Management LLC increased its stake in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after buying an additional 5,940 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after buying an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the third quarter worth about $92,000. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at $94,000. Finally, Intech Investment Management LLC purchased a new stake in Zevra Therapeutics during the 3rd quarter valued at approximately $95,000. 35.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZVRA. Guggenheim assumed coverage on Zevra Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $20.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Zevra Therapeutics in a report on Wednesday, January 8th. They set an "overweight" rating and a $25.00 price objective on the stock. Maxim Group boosted their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zevra Therapeutics presently has an average rating of "Buy" and an average price target of $21.57.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded up $0.12 during trading on Friday, hitting $8.05. 216,673 shares of the company's stock were exchanged, compared to its average volume of 459,061. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76. The firm has a 50-day moving average price of $8.70 and a two-hundred day moving average price of $7.75.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the business earned ($0.40) earnings per share. As a group, analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.